Clinical Trial News
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Get news by email or subscribe to our news feeds.
Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma
BEDFORD, Mass.--(BUSINESS WIRE)--May 20, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, a... Read more...
Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), together with CEPI, today announced it has... Read more...
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA
SINGAPORE, May 21, 2019 /PRNewswire/ -- iX Biopharma Ltd (42C.SI) announced today that following the completion of its Phase 2 clinical study on Wafermine, a... Read more...
Veritas Announces the Completion of Clinical Trial on their Cannabis Product for Treatment of Acute Pain
SAN JUAN, Puerto Rico, May 15, 2019 — Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2... Read more...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
Wednesday, May 15, 2019 - Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and... Read more...
FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2019-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and... Read more...
Pooled Analyses of the Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety
10 May 2019 AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat,... Read more...
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Tokyo and Basking Ridge, NJ – (May 14, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the outcome of the U.S. Food and Dru... Read more...
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor
Tokyo and Basking Ridge, NJ – (May 14, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Adm... Read more...
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
BASEL, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and... Read more...
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the... Read more...
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the... Read more...
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP® (emtricitabine ... Read more...
BioCryst Completes Phase 1 Clinical Trial of Galidesivir
RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized,... Read more...
CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals
VANCOUVER, Washington, May 08, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PR... Read more...
Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants
KENILWORTH, N.J.--(BUSINESS WIRE) May 8, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2... Read more...
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
INDIANAPOLIS, May 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational,... Read more...
FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need
VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PR... Read more...
AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients
Basel, May 5, 2019 - AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene... Read more...
Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that results of FORTITUDE-ALS ... Read more...
Clinical Trial Results Archive
2019January, February, March, April, May
2018January, February, March, April, May, June, July, August, September, October, November, December
2017January, February, March, April, May, June, July, August, September, October, November, December
2016January, February, March, April, May, June, July, August, September, October, November, December
2015January, February, March, April, May, June, July, August, September, October, November, December
2014January, February, March, April, May, June, July, August, September, October, November, December
2013January, February, March, April, May, June, July, August, September, October, November, December
2012January, February, March, April, May, June, July, August, September, October, November, December
2011January, February, March, April, May, June, July, August, September, October, November, December
2010January, February, March, April, May, June, July, August, September, October, November, December
2009January, February, March, April, May, June, July, August, September, October, November, December
2008January, February, March, April, May, June, July, August, September, October, November, December
2007January, February, March, April, May, June, July, August, September, October, November, December
2006December
2005April
2004January, June, July, October
2003November
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Generic Drug Approvals
- Monthly Update Archive
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
